Skip to main content

Ankylosing Spondylitis

ALN
In this video, Atul Deodhar, MD, provides an overview of results from a phase 3 study that assessed whether the oral JAK inhibitor tofacitinib could be a treatment option for adults with ankylosing spondylitis. He had presented on the topic at ACR Convergence.
ALN
Do you know whether ankylosing spondylitis affects patients with Crohn disease more often than those with ulcerative colitis, or vice versa? Find out by taking our pop quiz!
Rheumatology Consultant
Johan K. Wallman, MD, PhD, from Lund University, answers our questions about his research on the prevalence of gut symptoms meeting criteria for irritable bowel syndrome (IBS) among patients with axial spondyloarthritis compared with a control group.
Rheumatology Consultant
Authors of the MEASURE 3 study have shared their end‐of‐study 3‐year efficacy and safety results of secukinumab, 150 mg and 300 mg, among patients with active ankylosing spondylitis. Find out what the researchers determined.
Rheumatology Consultant
Jean Liew, MD, from the University of Washington, answers our questions about the relationship between cardiovascular risk and nonsteroidal anti-inflammatory drug use in the management of ankylosing spondylitis.
Back to Top